辉瑞(PFE.US)和BioNTech(BNTX.US)计划在8月份试验针对Delta异株疫苗

智通财经2021-07-09

智通财经APP获悉，辉瑞(PFE.US)和BioNTech(BNTX.US)正准备下个月开始针对Delta异株的Covid-19疫苗的临床试验，因为人们担心现有的疫苗对这种在全球大部分地区传播的毒株提供的保护不足。辉瑞周四表示，制药商正在开发现有疫苗的更新版本，将使用Delta异株的序列来生产。辉瑞和BioNTech正与美国药品监管机构进行讨论，以敲定它们的临床试验计划，预计将在8月开始研究。这...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

deelee
2021-07-09
deelee
又来，为什么PFE股票涨这么慢！

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2150377552?lang=zh_CN&edition=full","thumbnail":"https://static.tigerbbs.com/e559c5a8390713a5a8d4b07a2667368d","is_english":false,"pubTime":"2021-07-09 21:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2150377552","market":"hk","top_or_hot":-1,"title":"辉瑞(PFE.US)和BioNTech(BNTX.US)计划在8月份试验针对Delta异株疫苗","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，辉瑞(PFE.US)和BioNTech(BNTX.US)正准备下个月开始针对Delta异株的Covid-19疫苗的临床试验，因为人们担心现有的疫苗对这种在全球大部分地区传播的毒株提供的保护不足。辉瑞周四表示，制药商正在开发现有疫苗的更新版本，将使用Delta异株的序列来生产。辉瑞和BioNTech正与美国药品监管机构进行讨论，以敲定它们的临床试验计划，预计将在8月开始研究。这...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/511262.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>辉瑞(PFE.US)和BioNTech(BNTX.US)计划在8月份试验针对Delta异株疫苗</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n辉瑞(PFE.US)和BioNTech(BNTX.US)计划在8月份试验针对Delta异株疫苗\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-09 21:33 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/511262.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，辉瑞(PFE.US)和BioNTech(BNTX.US)正准备下个月开始针对Delta异株的Covid-19疫苗的临床试验，因为人们担心现有的疫苗对这种在全球大部分地区传播的毒株提供的保护不足。辉瑞周四表示，制药商正在开发现有疫苗的更新版本，将使用Delta异株的序列来生产。辉瑞和BioNTech正与美国药品监管机构进行讨论，以敲定它们的临床试验计划，预计将在8月开始研究。这...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/511262.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PFE","symbol_name":"辉瑞","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/511262.html","article_id":"2150377552","we_media_id":null,"thumbnails":["https://static.tigerbbs.com/e559c5a8390713a5a8d4b07a2667368d"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2150377552","pubTimestamp":1625837588,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，辉瑞和BioNTech正准备下个月开始针对Delta异株的Covid-19疫苗的临床试验，因为人们担心现有的疫苗对这种在全球大部分地区传播的毒株提供的保护不足。辉瑞和BioNTech正与美国药品监管机构进行讨论，以敲定它们的临床试验计划，预计将在8月开始研究。以色列卫生部本周的一项研究表明，BioNTech/辉瑞疫苗在预防Delta病毒引起的严重疾病和住院治疗方面的有效性为93%，但在防止感染该病毒变体方面的有效性仅为64%。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"PFE":"辉瑞"},"translate_title":"Pfizer (PFE.US) and BioNTech (BNTX.US) plan to test foreign vaccines against Delta in August","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFE":1},"content_text":"智通财经APP获悉，辉瑞(PFE.US)和BioNTech(BNTX.US)正准备下个月开始针对Delta异株的Covid-19疫苗的临床试验，因为人们担心现有的疫苗对这种在全球大部分地区传播的毒株提供的保护不足。辉瑞周四表示，制药商正在开发现有疫苗的更新版本，将使用Delta异株的序列来生产。辉瑞和BioNTech正与美国药品监管机构进行讨论，以敲定它们的临床试验计划，预计将在8月开始研究。这两家公司将率先研发针对Delta异株的疫苗，这表明这种高度传染性的毒株可能能够逃避现有的疫苗，需要采取新的措施来应对它。美国疾病控制与预防中心数据显示，Delta异株目前是美国的主要毒株，同时占英国新冠病毒病例的90%以上。辉瑞重申，在两针疫苗的第二针之后的6至12个月，需要第三针疫苗，以增强对新变种的免疫力。该公司表示，它将公布关于第三次注射效果的更明确数据，并计划在8月份向美国食品和药物管理局申请加强注射的紧急使用授权。辉瑞指出，上个月公布的初步数据显示，两剂疫苗产生了针对Delta变体的抗体滴度，但该公司表示，疫苗效力在接种6个月后出现下降。以色列卫生部本周的一项研究表明，BioNTech/辉瑞疫苗在预防Delta病毒引起的严重疾病和住院治疗方面的有效性为93%，但在防止感染该病毒变体方面的有效性仅为64%。而Moderna(MRNA.US)和强生(JNJ.US)均表示，早期数据显示，他们的疫苗产生了针对Delta的抗体。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":141380571,"gmtCreate":1625838776393,"gmtModify":1633936833196,"author":{"id":"3567856328974744","authorId":"3567856328974744","name":"deelee","avatar":"https://static.tigerbbs.com/0b0be180e4aaa7d467eb418c9066935d","vip":1,"crmLevel":7,"crmLevelSwitch":0,"idStr":"3567856328974744","authorIdStr":"3567856328974744"},"htmlText":"又来，为什么PFE股票涨这么慢！","listText":"又来，为什么PFE股票涨这么慢！","text":"又来，为什么PFE股票涨这么慢！","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/141380571","repostId":2150377552,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":0,"commentSize":1,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2150377552"}